178114-27-7

Upstream product

• 178114-28-8 4-(2-nitrophenyl)-2,4-dioxobutanoic acid ethyl ester 
• 577-59-3 2-acetylnitrobenzene 

Downstream Products

• 1257427-56-7 1-[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]-3-(2-nitrophenyl)-1H-pyrazole-5-carboxylic acid 
• 178114-22-2 ethyl 5-(2-aminophenyl)-1H-pyrazole-3-carboxylate 

Relevant academic research and scientific papers

AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF

The present invention relates to an aromatic derivative, a preparation method thereof and medical applications thereof. Particularly, the present invention relates to a novel compound as shown in the general formula (I) and a pharmaceutically acceptable s

AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: "Z", R1 and R2 are defined herein, which compounds are believed suitable for use in selectively antagonizing th

Synthesis and cytotoxicity evaluation of 1-[3-(9H-carbazol-4-yloxy)-2- hydroxypropyl]-3-aryl-1H-pyrazole-5-carboxylic acid derivatives

Several novel molecules, 1-(3′-(9H-carbazol-4-yloxy)-2′- hydroxypropyl)-3-aryl-1H-pyrazole-5-carboxylic acid derivatives 3a-g were synthesized and screened to evaluate their cytotoxicity against cancer cells in vitro. The compounds 3a-g has been prepared by the reaction of ethyl 3-aryl-1H-pyrazole-5-carboxylate with 4-oxiranylmethoxy-9H-carbazole in moderate to excellent yields. The cytotoxicity of synthesized compounds was evaluated by a SRB (sulforhodamine B) assay against cancer cell such as SK-N-SH human neuroblastoma (NB), human A549 lung carcinoma, human breast cancer MCF-7 cell lines. The results showed that seven compounds can suppress SK-N-SH tumor cancer cell growth. Among them, compound 3d was the most effective small molecule in inhibiting SK-N-SH cell growth.

Benzodiazepine binding activity of some tricyclic heteroatomic systems to define the hydrogen bonding strength of the proton donors of the receptor site

Comparison of the benzodiazepine receptor affinities of some known and newly synthesized tricyclic derivatives of similar size and shape, and bearing the same pharmacophoric descriptors allowed us to suggest the different hydrogen bonding power of the proton donors of the benzodiazepine receptor recognition site. In particular, we propose, according to a previous model, that the lack of the a1 acceptor, which corresponds to a weak hydrogen donor of the receptor site, is not crucial for receptor-ligand interaction but, like the hydrogen donor d, only affects the potency. On the contrary, the presence of a proton acceptor atom in the a2 area is essential for the anchoring of our tricyclic derivatives to the benzodiazepine receptor recognition site.